[New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects].

Dragomiretskaya, N A; Tarzimanova, A I; Kucherova, J S; Podzolkov, V I

Dragomiretskaya, N A; Tarzimanova, A I; Kucherova, J S; Podzolkov, V I.

Dragomiretskaya NA; Sechenov First Moscow State Medical University (Sechenov University).
Tarzimanova AI; Sechenov First Moscow State Medical University (Sechenov University).
Kucherova JS; Sechenov First Moscow State Medical University (Sechenov University).
Podzolkov VI; Sechenov First Moscow State Medical University (Sechenov University).

Ter Arkh ; 93(9): 1132-1137, 2021 Sep 15.

Article in Russian | MEDLINE | ID: covidwho-1486854

ABSTRACT

ABSTRACT

Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).

Subject(s)

COVID-19 Drug Treatment; Hypertension; Humans; Mineralocorticoid Receptor Antagonists/pharmacology; Mineralocorticoid Receptor Antagonists/therapeutic use; Spironolactone/pharmacology; Spironolactone/therapeutic use; Eplerenone/therapeutic use; Aldosterone; SARS-CoV-2; Hypertension/drug therapy

Keywords

COVID-19; Spironolactonum; aldosterone antagonists; antifibrotic effect; arterial hypertension; chronic heart failure

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hypertension Type of study: Experimental Studies / Prognostic study Limits: Humans Language: Russian Journal: Ter Arkh Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google